Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …

Background: Cholinesterase inhibitors (ChEIs) are the only drugs marketed for the treatment
of Alzheimer's disease. Despite numerous randomized controlled trials, the efficacy and …

Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and
has become an urgent public health problem in most areas of the world. Substantial …

Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …

Background: Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's
disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and …

Cholinesterase inhibitors (ChE-Is) are the standard of therapy for treatment of patients with
Alzheimer disease (AD) and are the only class of drugs approved by the Food and Drug …

Early research into Alzheimer's disease launched the cholinergic hypothesis, based on the
correlation between central cholinergic deficiency and clinical measures of cognitive …

ABSTRACT Introduction: The prevalence of Alzheimer's disease (AD) continues to rise,
while treatment options for cognitive impairment are limited. Acetylcholinesterase inhibitors …

This review provides an overview of the three most widely used cholinesterase (ChE)
inhibitors: donepezil, rivastigmine, and galantamine. Differences in pharmacologic profiles …

The deficiency in cholinergic neurotransmission in Alzheimer's disease has led to the
development of cholinesterase inhibitors as the first-line treatment for symptoms of this …